CDX-1127

DRUG2 trials

Sponsors

Celldex Therapeutics, Craig L Slingluff, Jr

Conditions

Any T-cell MalignancyBurkett's LymphomaCD27 Expressing B-cell Malignancies for Example Hodgkin's LymphomaChronic Lymphocytic LeukemiaColorectal Adenocarcinoma, Non-small Cell Lung Cancer)Hormone-refractory Prostate Adenocarcinoma, Ovarian CancerMantle Cell LymphomaMarginal Zone B Cell Lymphoma)

Phase 1

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

CompletedNCT01460134

Celldex TherapeuticsAny T-cell Malignancy, Burkett's Lymphoma, CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma +7

Start: 2011-10-31End: 2017-10-16Updated: 2018-01-31

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

CompletedNCT03617328

Craig L Slingluff, JrMelanoma

Start: 2018-11-13End: 2024-01-19Updated: 2024-02-06

Related Papers

Adjuvant polypeptide vaccines for high-risk uveal melanoma.

Journal of Clinical Oncology2023-06-013 citations

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies

Blood Advances2020-05-0769 citations

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Blood2019-11-135 citations

RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial.

2018-11-096 citations

Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies.

Journal of Clinical Oncology2014-05-2024 citations

Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors.

Journal of Clinical Oncology2014-05-2012 citations